Strategic Collaborations & Global Partnerships
To amplify our mission and broaden patient access, OctaGenix works closely with globally trusted health organisations, regulatory bodies, and humanitarian partners. These collaborations ensure that our medicines are delivered efficiently, ethically, and in alignment with international best practices.

Our key collaborations include:

• National Health Ministries and Government Procurement Agencies across the CIS, Africa, the Middle East, and South Asia, supporting national programmes in oncology, anti-infectives, critical care, and chronic diseases.

• WHO-aligned procurement channels, enabling supply of essential medicines that meet the highest global standards for quality and safety.

• Partnerships with UNICEF supply initiatives and humanitarian distributors for paediatric formulations, emergency medicines, and vaccines in underserved regions.

• Engagement with UNDP, USAID, Global Fund distributors, and other development partners to improve access to essential therapeutics for infectious diseases, maternal health, and emergency care.

• Established relationships with EMA-, MHRA-, and FDA-regulated partners, supporting regulatory submissions, dossier preparation, and market authorisations worldwide.

• Strategic alliances with leading hospital groups, procurement agencies, and global wholesalers to strengthen pharmaceutical supply chains and ensure continuity of care.

• Joint collaborations with academic institutions and scientific networks to advance biosimilar development, innovation in formulary design, and evidence-based medicine optimisation.

• These partnerships allow us to extend our reach, scale our impact, and bring high-quality therapies to communities that need them most, reinforcing OctaGenix’s role as a trusted catalyst in global healthcare transformation.

Our Commitment to Health Equity
At the heart of OctaGenix’s mission is a profound commitment to health equity. We collaborate with governments, ministries of health, and international stakeholders to deliver affordable, high-quality generic alternatives to originator medicines. By dramatically reducing treatment costs
without compromising quality, we widen access to essential therapies in low- and middle-income countries, with a particular focus on CIS nations and other underserved markets.
A Vision for a Healthier Future
Every product we manufacture reflects our broader vision; to reduce global mortality and morbidity by ensuring equitable access to both essential and innovative therapies. Our work extends far beyond commercial objectives. It is rooted in the principles of human dignity, universal healthcare rights, and a steadfast belief that no individual should be denied treatment because of financial constraints or geographic limitations. Together with our partners, we are reshaping the future of medicine; one product, one patient, and one community at a time. Through collaboration, innovation, and purpose, we are building healthier societies, stronger healthcare systems, and a more equitable future for all